Fulcrum therapeutics appoints judith a. dunn, ph.d.

Cambridge, mass., march 24, 2021 (globe newswire) -- fulcrum therapeutics, inc.  (nasdaq: fulc), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that judith a. dunn, ph.d. has been appointed president of research and development. dr. dunn has held multiple leadership roles in global research and drug development spanning from discovery through commercialization. most recently, she supported the development of new companies targeting areas of unmet need in neuroscience as an entrepreneur in residence at atlas venture.
FULC Ratings Summary
Quant
FULC Quant Ranking
Sector
Industry
Quant Rating
Quant Score